Clinical trial · Interventional
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
Neoadjuvant Chemotherapy for Pancreatic Cancer; GS vs. GnP
NCT05268692CI-TRIAL-00056915recruitingPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The effect of neoadjuvant chemotherapy for pancreatic cancer was gradually established. However it has been not clarified which regimen of neoadjuvant treatment for pancreatic cancer is the best.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GnP | Drug | — | UNRESOLVED |
| GS | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- GS
- description
- gemcitabine plus S-1
- interventionNames
- Drug: GS
- type
- ACTIVE_COMPARATOR
- label
- GnP
- description
- gemcitabine plus nab-paclitaxel
- interventionNames
- Drug: GnP
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- 5 years
- description
- postoperative survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: elective pancreatectomy for pancreatic cancer Exclusion Criteria: a previous cancer surgery a body weight loss of \>10% during the 6 months before surgery the presence of distant metastases seriously impaired function of vital organs because of respiratory, renal, or heart disease.
References
Publications (0)
Data not yet available
No reference posted for this study.